Actavis Testosterone Drug Flouts 6 Patents, Eli Lilly Says

By Alex Lawson (November 14, 2013, 3:19 PM EST) -- Eli Lilly & Co. hit generic drugmaker Actavis Inc. and its subsidiaries with a suit Tuesday in Indiana federal court claiming that the company infringed six patents covering Eli Lilly's Axiron, a topical treatment used by men afflicted with low testosterone.

The complaint targets an abbreviated new drug application filed with the U.S. Food and Drug Administration detailing the plans of Actavis and a pair of its subsidiaries to manufacture and market a generic version of Axiron before the expiration of six Eli Lilly patents on the drug.

"Defendants plan to make, use, sell, offer to sell and/or import Actavis's generic...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!